Finally, the results provide a structural framework to rationalize the mode of neutralization of antibodies targeting the conserved fusion machinery. Results Protease-Mediated Fusion Activation of
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor